The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.

In this Q&A, Rob Stransky of NiceRx explains how to screen patients for gray-market retatrutide use and why cost drives demand for unregulated peptides.

New analyses from VESALIUS-CV and the FOURIER open-label extension add stroke and long-term outcome data for evolocumab.

Biykem Bozkurt, MD, PhD, explains why survodutide, a glucagon and GLP-1 dual agonist, needed a cardiovascular safety trial in patients with obesity.

Michael Mina, MD, PhD, discusses testing VMS063 against measles B3 and D8 genotypes and how it could fit alongside vaccination.

SCOUT-HCM 56-week data show sustained LVOT gradient reductions with mavacamten and no LVEF below 50% in adolescents with obstructive HCM.

Oncology leaders say clinical pathways must shift from static documents to tools that use patient-reported outcomes and AI to guide care.

Curing vitiligo isn't currently possible, and Dr. Desai says saying so plainly builds trust. He explains how he sets realistic, patient-specific goals around activity control and repigmentation.

Cancer care demand is constantly shifting, with panelists at PCOC 2026 debating the benefits of automation vs retaining live patient access.

The glucagon/GLP-1 dual agonist is noninferior to placebo for major adverse cardiovascular events and lowers blood pressure ...

The University of Exeter’s David Halpin, MA, DPhil, explains why GOLD 2026 treats a single COPD exacerbation as a trigger to ...

Most patients with MASH stay on resmetirom at 1 year, but Medicaid coverage was tied to lower odds of filling a first ...